by Primary sclerosing cholangitis (PSC) is a progressive liver disease characterized by inflammation and scarring of the bile ducts that causes them to narrow. Symptoms include fatigue, itching, jaundice, abdominal pain and dark urine. PSC patients also have increased risk of developing liver cancer. No approved therapies currently exist to treat the underlying condition, though ursodeoxycholic acid is used to help manage symptoms. The global primary sclerosing cholangitis market is dominated by symptomatic therapies targeting symptoms such as itching and pain management. The need for safe and effective treatments for PSC is growing as incidence and prevalence rates rise.
The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the primary sclerosing cholangitis market is rising research into novel therapies targeting the underlying disease pathology. Several biotech companies are developing agents targeting pathways involved in bile duct inflammation and fibrosis. For example, treatments targeting lysophosphatidic acid receptor, hepatocyte growth factor, and fibroblast growth factor 19 pathways are in early to mid-stage clinical trials. Researchers are also exploring fecal microbiota transplantation and budesonide as potential therapies. These novel treatment approaches aim to halt disease progression and prevent complications in PSC patients. If successful, they could transform the current treatment landscape that is dominated by symptomatic therapies alone.
Porter’s Analysis
Threat of new entrants: Low-moderate. Treatment of primary sclerosing cholangitis requires specialized drugs and medical expertise, making entry difficult.
Bargaining power of buyers: Moderate. Presence of few treatment options provides some bargaining power to buyers.
Bargaining power of suppliers: Moderate-high. Specialized drugs and therapies have limited substitutes, giving suppliers bargaining leverage.
Threat of new substitutes: Low-moderate. Novel therapies are in the pipeline but proven alternatives are still scarce.
Competitive rivalry: Moderate-high. Major companies are actively engaged in product development for this rare indication.
Key Takeaways
The global Primary Sclerosing Cholangitis Market Growth is expected to witness high growth over the forecast period of 2023 to 2030. The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.
North America is currently the largest as well as the fastest growing regional market for primary sclerosing cholangitis. The United States accounts for the major share in the North American market owing to high prevalence and growing awareness about the disease. Europe is another sizable regional market for primary sclerosing cholangitis. Countries like Germany, United Kingdom, and France have a significant patient population and are major revenue generators. However, the Asia Pacific region is anticipated to showcase fastest growth during the forecast period driven by expanding healthcare infrastructure and increasing discretionary spending on rare disease treatment in emerging economies.
Key players
Key players operating in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd. Major companies are focusing on developing novel therapies for better outcomes.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
